Patent number: 10806712
Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.
Type:
Grant
Filed:
March 11, 2019
Date of Patent:
October 20, 2020
Assignees:
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Inventors:
James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas Lawrence, Harshani Rithma Lawrence, Benjamin Greedy
Patent number: 10226439
Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.
Type:
Grant
Filed:
March 24, 2017
Date of Patent:
March 12, 2019
Assignees:
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Inventors:
James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas Lawrence, Harshani Rithma Lawrence, Benjamin Greedy
Patent number: 9604923
Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S31-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.
Type:
Grant
Filed:
April 7, 2014
Date of Patent:
March 28, 2017
Assignees:
H.LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Inventors:
James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas Lawrence, Harshani Rithma Lawrence, Benjamin Greedy
